Printer Friendly

Articles from M2 Pharma (August 6, 2018)

1-25 out of 25 article(s)
Title Author Type Words
Abzena signs GMP manufacturing and bioconjugation agreements with Telix Pharmaceuticals. 221
Antioxidant Pycnogenol Effective in Improving Symptoms of Mild Cognitive Impairment, New Research Shows. 595
Ascletis' Ravidasvir recommended as pan-genotypic DAA by the WHO HCV guidelines. 209
Astrazeneca announces grant of Orphan Designation by EMA for selumetinib in NF1. 402
Bluebird bio Presents Updated Data for Lenti-D Gene Therapy for Cerebral Adrenoleukodystrophy. 570
Celtaxsys announces clinically meaningful improvements in phase two cystic fibrosis trial of Acebilustat. Clinical report 168
China Biologic Products Holdings reports Q2 and H1 2018 financial results. Financial report 213
FDA approves Elite's generic methadone hydrochloride tablets. 149
Getinge announces US launch of 9100E Cart utensil washer for sterile processing departments in healthcare centres. 285
IAVI, the Public Health Agency of Canada Enter into License Agreement for Technology to Enable Lassa Fever Vaccine Development. 539
Jazz Pharmaceuticals' Vyxeos receives US Centers for Medicare and Medicaid Services approval for New Technology Add-on Payment. 193
Korea recalls hypertension drugs over cancer risks. 287
MagArray Launches Reveal Blood Test for Lung Cancer Risk Assessment. 233
Neovasc signs collaboration and licensing agreement with Penn to advance Tiara programme for mitral valve disease. 222
Nitto Denko Avecia Inc announces planned departure of president Detlef Rethage. 144
Oxford BioMedica forms cystic fibrosis partnership. 290
PharmaMar wins US FDA orphan drug designation for lurbinectedin for small cell lung cancer. 192
Pulmatrix incurs higher net loss USD6.2m for Q2 2018. Financial report 159
Recruitment completed for Paradigm Biopharmaceuticals' knee pain trial. 135
Selumetinib Granted Orphan Designation in Europe for Neurofibromatosis Type 1. 772
The National Kidney Foundation (NKF), The Alport Syndrome Foundation and the US FDA conduct patient-focused meeting for Alport Syndrome. 292
Titan reports amended agreement with Molteni for Probuphine. 272
Trovagene reports Q2 2018 financial results. Financial report 170
US FDA Clears Hologic's Panther Fusion GBS Assay. 515
William Demant Holding partners with Philip to provide hearing healthcare. 183

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |